---
title: "Humacyte - CW27 | 10-Q: FY2025 Q3 Revenue: USD 753 K"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265595756.md"
datetime: "2025-11-12T22:09:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265595756.md)
  - [en](https://longbridge.com/en/news/265595756.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265595756.md)
generator: "portal-rs"
---

# Humacyte - CW27 | 10-Q: FY2025 Q3 Revenue: USD 753 K

Revenue: As of FY2025 Q3, the actual value is USD 753 K.

EPS: As of FY2025 Q3, the actual value is USD -0.11.

EBIT: As of FY2025 Q3, the actual value is USD -22.37 M.

### Segment Revenue

-   **Product Revenue, Net**: $703 thousand for the three months ended September 30, 2025, and $950 thousand for the nine months ended September 30, 2025.
-   **Contract Revenue**: $50 thousand for the three months ended September 30, 2025, and $621 thousand for the nine months ended September 30, 2025.

### Operational Metrics

-   **Cost of Goods Sold**: $260 thousand for the three months ended September 30, 2025, and $620 thousand for the nine months ended September 30, 2025.
-   **Research and Development Expenses**: $17.3 million for the three months ended September 30, 2025, a decrease of 25% from $22.9 million for the same period in 2024. For the nine months ended September 30, 2025, $54.7 million, a decrease of 19% from $67.9 million in 2024.
-   **Selling, General and Administrative Expenses**: $7.6 million for the three months ended September 30, 2025, an increase of 4% from $7.3 million in 2024. For the nine months ended September 30, 2025, $23.6 million, an increase of 28% from $18.4 million in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: $78.9 million for the nine months ended September 30, 2025, compared to $71.5 million for the same period in 2024.
-   **Net Cash Used in Investing Activities**: $845 thousand for the nine months ended September 30, 2025, compared to $1.5 million in 2024.
-   **Net Cash Provided by Financing Activities**: $4.3 million for the nine months ended September 30, 2025, compared to $63.2 million in 2024.

### Unique Metrics

-   **Change in Fair Value of Contingent Earnout Liability**: $4.9 million gain for the three months ended September 30, 2025, compared to an $8.5 million loss in 2024. For the nine months ended September 30, 2025, $49.2 million gain compared to a $38.7 million loss in 2024.
-   **Change in Fair Value of Derivatives**: $4.0 million gain for the three months ended September 30, 2025, compared to $1.0 million in 2024. For the nine months ended September 30, 2025, $18.2 million gain compared to $0.7 million in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to commercialize Symvess in the U.S. for vascular trauma and, if approved, in AV access for hemodialysis. It aims to obtain marketing approval for its 6 millimeter ATEV in additional indications and scale its manufacturing facility to meet potential market demand.
-   **Non-Core Business**: The company is exploring applications of its technology across a broad range of markets and indications, including the development of urinary conduit, trachea, esophagus, and other novel cell delivery systems.

### Related Stocks

- [HUMAW.US](https://longbridge.com/en/quote/HUMAW.US.md)

## Related News & Research

- [Zscaler (ZS) Is Down 5.1% After Issuing 2027 Guidance And Filing US$1.69 Billion Shelf Registration – Has The Bull Case Changed?](https://longbridge.com/en/news/298038986.md)
- [Michael Burry Called This Stock the 'Trickster' in His Portfolio: Says It's 'Determined' to Take Him Where 'Mermaids Fear to Tread'](https://longbridge.com/en/news/297990287.md)
- [McDonald's Stock (MCD) Hits 52-Week Low. Here's What's Holding Back the Burger Chain](https://longbridge.com/en/news/298057026.md)
- [Lululemon's Comparable Sales Fell 9%. Can New CEO Heidi O'Neill Turn Things Around or Is the Brand Broken?](https://longbridge.com/en/news/298017136.md)
- [Alibaba Expands Equity Base with HK$112.7 Placement of 710 Million New Shares](https://longbridge.com/en/news/298029562.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**